Cargando…
Purification and characterization of mutant miniPlasmin for thrombolytic therapy
BACKGROUND: Previous animal studies by us and others have indicated that catheter-administered plasmin or its des-kringle derivatives may be more appropriate alternatives to plasminogen activators for treating thrombolytic diseases, since it has a very short serum half-life and therefore does not re...
Autores principales: | Lin, Xiaotao, Wang, Yan, Zhang, Yanwen, Huang, Bing, Lin, James J, Hallock, Scott J, Yu, Hong, Shao, Hongwei, Yan, Jing, Huang, Bo, Zhang, Xuejun C, Cao, Wei, Xu, Xueming, Lin, Xinli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724493/ https://www.ncbi.nlm.nih.gov/pubmed/23363549 http://dx.doi.org/10.1186/1477-9560-11-2 |
Ejemplares similares
-
Identification and Characterization of Plasmin-Independent Thrombolytic Enzymes
por: Hassan, Md. Mehedi, et al.
Publicado: (2020) -
Site-specific PEGylation of micro-plasmin for improved thrombolytic therapy through engineering enhanced resistance against serpin mediated inhibition
por: Kaur, Navneet, et al.
Publicado: (2019) -
Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer
por: Yan, Yan, et al.
Publicado: (2020) -
Development of an in vitro model to study clot lysis activity of thrombolytic drugs
por: Prasad, Sweta, et al.
Publicado: (2006) -
STUDIES OF THE PLASMIN SYSTEM : II. INHIBITION OF PLASMIN BY SERUM OR PLASMA
por: Norman, Philip S.
Publicado: (1958)